Arrowhead Pharmaceuticals, INC.: directors' dealings · United States · SEC (Form 4)

About Arrowhead Pharmaceuticals, INC.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is a United States-based biopharmaceutical company focused on RNA interference (RNAi) therapeutics, a gene-silencing approach designed to shut down disease-causing proteins at the source. The company is headquartered in Pasadena, California, with major research and development operations in Madison, Wisconsin and San Diego, California, plus chemistry and manufacturing capabilities in Verona, Wisconsin. Founded in May 2003, Arrowhead has spent more than two decades building scientific capabilities around RNAi delivery and target selection, now centered on its proprietary TRiM™ platform. From an industry standpoint, Arrowhead sits in the specialized precision-medicine segment of healthcare, with a business model that combines platform innovation, internal pipeline development, and an emerging commercial footprint. Its strategy is to apply RNAi across multiple disease areas rather than rely on a single therapeutic niche. Management describes TRiM™ as tissue-agnostic, enabling the company to pursue cardiometabolic, liver, pulmonary, neurological and other hard-to-treat conditions. That breadth is a competitive strength because it creates multiple shots on goal, although the company still faces the usual biotech challenges of clinical execution, regulatory approval and commercialization. A major recent milestone is the FDA approval of REDEMPLO® (plozasiran) in November 2025 for adults with familial chylomicronemia syndrome (FCS), a rare and severe disorder characterized by extremely elevated triglycerides and a high risk of pancreatitis. In December 2025, plozasiran also received FDA Breakthrough Therapy designation in severe hypertriglyceridemia, and in 2026 Arrowhead announced a positive CHMP opinion in Europe. These developments are important because they validate the platform clinically and move Arrowhead from a pure development story toward a company with its first marketed asset and the possibility of broader international expansion. Beyond plozasiran, Arrowhead continues to advance a pipeline of RNAi candidates in obesity and other cardiometabolic indications, as well as programs that explore newer delivery systems and potential central nervous system applications. The company’s competitive position is therefore based less on scale than on scientific differentiation, delivery technology and the ability to convert platform assets into approvable medicines. For investors in French-speaking markets, Arrowhead represents a high-upside, high-risk U.S. NASDAQ-listed biotech with meaningful pipeline optionality, a first commercial product, and a clear focus on gene-silencing therapeutics.